Delayed Rise of Oral Fluid Antibodies, Elevated BMI, and Absence of Early Fever Correlate With Longer Time to SARS-CoV-2 RNA Clearance in a Longitudinally Sampled Cohort of COVID-19 Outpatients
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: Sustained molecular detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in the upper respiratory tract (URT) in mild to moderate coronavirus disease 2019 (COVID-19) is common. We sought to identify host and immune determinants of prolonged SARS-CoV-2 RNA detection.
METHODS: Ninety-five symptomatic outpatients self-collected midturbinate nasal, oropharyngeal (OP), and gingival crevicular fluid (oral fluid) samples at home and in a research clinic a median of 6 times over 1-3 months. Samples were tested for viral RNA, virus culture, and SARS-CoV-2 and other human coronavirus antibodies, and associations were estimated using Cox proportional hazards models.
RESULTS: Viral RNA clearance, as measured by SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR), in 507 URT samples occurred a median (interquartile range) 33.5 (17-63.5) days post-symptom onset. Sixteen nasal-OP samples collected 2-11 days post-symptom onset were virus culture positive out of 183 RT-PCR-positive samples tested. All participants but 1 with positive virus culture were negative for concomitant oral fluid anti-SARS-CoV-2 antibodies. The mean time to first antibody detection in oral fluid was 8-13 days post-symptom onset. A longer time to first detection of oral fluid anti-SARS-CoV-2 S antibodies (adjusted hazard ratio [aHR], 0.96; 95% CI, 0.92-0.99; P = .020) and body mass index (BMI) ≥25 kg/m2 (aHR, 0.37; 95% CI, 0.18-0.78; P = .009) were independently associated with a longer time to SARS-CoV-2 viral RNA clearance. Fever as 1 of first 3 COVID-19 symptoms correlated with shorter time to viral RNA clearance (aHR, 2.06; 95% CI, 1.02-4.18; P = .044).
CONCLUSIONS: We demonstrate that delayed rise of oral fluid SARS-CoV-2-specific antibodies, elevated BMI, and absence of early fever are independently associated with delayed URT viral RNA clearance.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 8(2021), 6 vom: 01. Juni, Seite ofab195 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 16.02.2024 published: Electronic-eCollection UpdateOf: medRxiv. 2021 Mar 03;:. - PMID 33688688 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofab195 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32643562X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32643562X | ||
| 003 | DE-627 | ||
| 005 | 20240216232140.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofab195 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1295.xml |
| 035 | |a (DE-627)NLM32643562X | ||
| 035 | |a (NLM)34095338 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Antar, Annukka A R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Delayed Rise of Oral Fluid Antibodies, Elevated BMI, and Absence of Early Fever Correlate With Longer Time to SARS-CoV-2 RNA Clearance in a Longitudinally Sampled Cohort of COVID-19 Outpatients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a UpdateOf: medRxiv. 2021 Mar 03;:. - PMID 33688688 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Sustained molecular detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in the upper respiratory tract (URT) in mild to moderate coronavirus disease 2019 (COVID-19) is common. We sought to identify host and immune determinants of prolonged SARS-CoV-2 RNA detection | ||
| 520 | |a METHODS: Ninety-five symptomatic outpatients self-collected midturbinate nasal, oropharyngeal (OP), and gingival crevicular fluid (oral fluid) samples at home and in a research clinic a median of 6 times over 1-3 months. Samples were tested for viral RNA, virus culture, and SARS-CoV-2 and other human coronavirus antibodies, and associations were estimated using Cox proportional hazards models | ||
| 520 | |a RESULTS: Viral RNA clearance, as measured by SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR), in 507 URT samples occurred a median (interquartile range) 33.5 (17-63.5) days post-symptom onset. Sixteen nasal-OP samples collected 2-11 days post-symptom onset were virus culture positive out of 183 RT-PCR-positive samples tested. All participants but 1 with positive virus culture were negative for concomitant oral fluid anti-SARS-CoV-2 antibodies. The mean time to first antibody detection in oral fluid was 8-13 days post-symptom onset. A longer time to first detection of oral fluid anti-SARS-CoV-2 S antibodies (adjusted hazard ratio [aHR], 0.96; 95% CI, 0.92-0.99; P = .020) and body mass index (BMI) ≥25 kg/m2 (aHR, 0.37; 95% CI, 0.18-0.78; P = .009) were independently associated with a longer time to SARS-CoV-2 viral RNA clearance. Fever as 1 of first 3 COVID-19 symptoms correlated with shorter time to viral RNA clearance (aHR, 2.06; 95% CI, 1.02-4.18; P = .044) | ||
| 520 | |a CONCLUSIONS: We demonstrate that delayed rise of oral fluid SARS-CoV-2-specific antibodies, elevated BMI, and absence of early fever are independently associated with delayed URT viral RNA clearance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a RT-PCR | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody | |
| 650 | 4 | |a viral RNA | |
| 700 | 1 | |a Yu, Tong |e verfasserin |4 aut | |
| 700 | 1 | |a Pisanic, Nora |e verfasserin |4 aut | |
| 700 | 1 | |a Azamfirei, Razvan |e verfasserin |4 aut | |
| 700 | 1 | |a Tornheim, Jeffrey A |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Diane M |e verfasserin |4 aut | |
| 700 | 1 | |a Kruczynski, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Hardick, Justin P |e verfasserin |4 aut | |
| 700 | 1 | |a Sewell, Thelio |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Minyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Church, Taylor |e verfasserin |4 aut | |
| 700 | 1 | |a Walch, Samantha N |e verfasserin |4 aut | |
| 700 | 1 | |a Reuland, Carolyn |e verfasserin |4 aut | |
| 700 | 1 | |a Bachu, Vismaya S |e verfasserin |4 aut | |
| 700 | 1 | |a Littlefield, Kirsten |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Han-Sol |e verfasserin |4 aut | |
| 700 | 1 | |a Ursin, Rebecca L |e verfasserin |4 aut | |
| 700 | 1 | |a Ganesan, Abhinaya |e verfasserin |4 aut | |
| 700 | 1 | |a Kusemiju, Oyinkansola |e verfasserin |4 aut | |
| 700 | 1 | |a Barnaba, Brittany |e verfasserin |4 aut | |
| 700 | 1 | |a Charles, Curtisha |e verfasserin |4 aut | |
| 700 | 1 | |a Prizzi, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Johnstone, Jaylynn R |e verfasserin |4 aut | |
| 700 | 1 | |a Payton, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Weiwei |e verfasserin |4 aut | |
| 700 | 1 | |a Fuchs, Joelle |e verfasserin |4 aut | |
| 700 | 1 | |a Massaccesi, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Armstrong, Derek T |e verfasserin |4 aut | |
| 700 | 1 | |a Townsend, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Keller, Sara C |e verfasserin |4 aut | |
| 700 | 1 | |a Demko, Zoe O |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Mei-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Sauer, Lauren M |e verfasserin |4 aut | |
| 700 | 1 | |a Mostafa, Heba H |e verfasserin |4 aut | |
| 700 | 1 | |a Keruly, Jeanne C |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Shruti H |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Sabra L |e verfasserin |4 aut | |
| 700 | 1 | |a Cox, Andrea L |e verfasserin |4 aut | |
| 700 | 1 | |a Pekosz, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Heaney, Christopher D |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, David L |e verfasserin |4 aut | |
| 700 | 1 | |a Blair, Paul W |e verfasserin |4 aut | |
| 700 | 1 | |a Manabe, Yukari C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 8(2021), 6 vom: 01. Juni, Seite ofab195 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2021 |g number:6 |g day:01 |g month:06 |g pages:ofab195 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofab195 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2021 |e 6 |b 01 |c 06 |h ofab195 | ||